Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Michael R. Grunwald, MD, FACP, hematologist/ oncologist, chief, Leukemia Division; director, Transplantation and Cellular Therapy Program, Levine Cancer Institute, Atrium Health, discusses the rates and incidence of disease progression in patients with low-risk myelofibrosis who were enrolled in the prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST; NCT02953704).

Related Content:

Atrium Health Levine CancerEuropean Hematology Association CongressOncLive TVConferenceHematologic Oncology
Dr Trent on the Efficacy of Bezuclastinib Plus Sunitinib in Pretreated GIST
Dr Sekeres on Outcomes from the ASTREON Trial in Low- to Intermediate-Risk MDS
Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC